<DOC>
	<DOCNO>NCT02634320</DOCNO>
	<brief_summary>This study evaluate safety tolerability aripiprazole lauroxil ( also know ARISTADA , ALKS 9070 ) .</brief_summary>
	<brief_title>A Study Aripiprazole Lauroxil ( Also Known ARISTADA TM ) Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Has demonstrate tolerability test dose oral aripiprazole screening ; OR history tolerate use aripiprazole Has diagnosis schizophrenia Is clinically stable Has receive least 3 dos risperidone long act injection ( Risperdal Consta ) paliperidone palmitate ( Invega Sustenna ) prior screen . Has antipsychotic medication regimen change 4 week prior Day 1 Agreed abide contraceptive requirement protocol Resides stable living situation Additional criterion may apply Is currently pregnant breastfeeding , plan become pregnant study Has receive Invega Trinza , aripiprazole lauroxil , IM depot aripiprazole within 6 month screen Has participate clinical trial involve investigational product within past 3 month , currently participate clinical trial involve investigational product Has positive urine drug test illicit use amphetamine , barbiturate , cocaine , methadone , opiates , phencyclidine screen Additional criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ARISTADA</keyword>
	<keyword>Aripiprazole Lauroxil</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>